Recro Pharma Company Profile (NASDAQ:REPH)

About Recro Pharma

Recro Pharma logoRecro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: REPH
  • CUSIP:
Key Metrics:
  • Previous Close: $7.31
  • 50 Day Moving Average: $7.62
  • 200 Day Moving Average: $8.08
  • 52-Week Range: $12,163,000.00 - $5.59
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.78
  • P/E Growth: 0.00
  • Market Cap: $88.91M
  • Outstanding Shares: 12,163,000
  • Beta: -0.62
Profitability:
  • Net Margins: -13.34%
  • Return on Equity: -57.17%
  • Return on Assets: -15.22%
Debt:
  • Debt-to-Equity Ratio: 0.56%
  • Current Ratio: 4.35%
  • Quick Ratio: 3.48%
Additional Links:
Companies Related to Recro Pharma:

Analyst Ratings

Consensus Ratings for Recro Pharma (NASDAQ:REPH) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.67 (169.04% upside)

Analysts' Ratings History for Recro Pharma (NASDAQ:REPH)
Show:
DateFirmActionRatingPrice TargetDetails
12/19/2016Piper Jaffray CompaniesInitiated CoverageOverweight$12.00View Rating Details
11/29/2016HC WainwrightReiterated RatingBuy$19.00View Rating Details
11/28/2016Roth CapitalSet Price TargetBuy$24.00View Rating Details
11/14/2016AegisInitiated CoverageBuy$21.00View Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$21.00View Rating Details
8/29/2016Janney Montgomery ScottInitiated CoverageBuy$21.00View Rating Details
4/14/2015MLV & Co.Boost Price TargetBuy$12.00 -> $22.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Recro Pharma (NASDAQ:REPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/22/2017        
8/11/2016Q2($0.78)($0.83)$18.70 million$17.30 millionViewN/AView Earnings Details
5/12/2016Q1($0.66)($0.71)$13.00 million$17.70 millionViewN/AView Earnings Details
3/24/2016Q4($0.43)$1.13ViewN/AView Earnings Details
11/9/2015Q3($0.20)($0.24)ViewN/AView Earnings Details
5/13/2015Q115($0.52)($0.53)ViewN/AView Earnings Details
3/25/2015Q414($0.68)($0.45)ViewN/AView Earnings Details
11/10/2014Q314($0.51)($0.61)ViewN/AView Earnings Details
8/12/2014($0.25)($0.36)ViewN/AView Earnings Details
5/12/2014($0.36)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Recro Pharma (NASDAQ:REPH)
Current Year EPS Consensus Estimate: $-2.94 EPS
Next Year EPS Consensus Estimate: $-2.63 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20161($1.09)($1.09)($1.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Recro Pharma (NASDAQ:REPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Recro Pharma (NASDAQ:REPH)
Insider Ownership Percentage: 39.30%
Institutional Ownership Percentage: 53.23%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/17/2017Scp Vitalife Partners Ii LpMajor ShareholderSell9,983$7.59$75,770.97View SEC Filing  
2/16/2017Scp Vitalife Partners (Israel)Major ShareholderSell4,030$7.89$31,796.70View SEC Filing  
12/16/2016Karen FlynnDirectorBuy800$6.71$5,368.00View SEC Filing  
12/15/2016Alfred AltomariDirectorBuy1,500$6.55$9,825.00View SEC Filing  
12/13/2016Healthcare Master Fun BroadfinMajor ShareholderBuy650,000$6.00$3,900,000.00View SEC Filing  
8/16/2016Healthcare Master Fun BroadfinMajor ShareholderBuy390,000$7.50$2,925,000.00View SEC Filing  
5/31/2016Stewart MccallumInsiderBuy1,250$8.22$10,275.00View SEC Filing  
5/23/2016Randall MackVPBuy2,000$6.30$12,600.00View SEC Filing  
5/23/2016Scp Vitalife Partners (Israel)Major ShareholderSell2,503$6.30$15,768.90View SEC Filing  
5/20/2016Scp Vitalife Partners (Israel)Major ShareholderSell6,260$6.46$40,439.60View SEC Filing  
5/20/2016Winston J ChurchillDirectorSell58,331$7.91$461,398.21View SEC Filing  
5/19/2016Donna NicholsCAOBuy1,140$6.48$7,387.20View SEC Filing  
11/27/2015Scp Vitalife Partners Ii Lpmajor shareholderSell11,385$9.00$102,465.00View SEC Filing  
11/24/2015Scp Vitalife Partners (Israel)major shareholderSell4,393$9.00$39,537.00View SEC Filing  
7/7/2015Healthcare Master Fun BroadfinMajor ShareholderBuy646,553$11.60$7,500,014.80View SEC Filing  
6/8/2015Geraldine HenwoodCEOBuy4,500$8.92$40,140.00View SEC Filing  
6/5/2015Charles GarnerCFOBuy2,000$8.50$17,000.00View SEC Filing  
12/2/2014Healthcare Master Fun BroadfinMajor ShareholderBuy241,338$2.50$603,345.00View SEC Filing  
5/15/2014Charles GarnerCFOBuy3,000$6.69$20,070.00View SEC Filing  
5/15/2014Donna NicholsCAOBuy1,200$6.66$7,992.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Recro Pharma (NASDAQ:REPH)
DateHeadline
finance.yahoo.com logoRecro Pharma Completes Enrollment in Phase III Safety Study of IV Meloxicam (NASDAQ:REPH)
finance.yahoo.com - February 27 at 9:33 AM
biz.yahoo.com logoRECRO PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:REPH)
biz.yahoo.com - February 27 at 9:33 AM
News IconMetrics in Focus: Recro Pharma, Inc. (NASDAQ:REPH) - Midway Monitor (NASDAQ:REPH)
midwaymonitor.com - February 23 at 12:41 AM
News IconEarnings Analysis & Update for Recro Pharma, Inc. (NASDAQ:REPH)? - Aiken Advocate (NASDAQ:REPH)
aikenadvocate.com - February 18 at 8:18 AM
News IconRecro Pharmaceuticals Sell For 19.7% Win In 11 Days (NASDAQ:REPH)
www.guerillastocktrading.com - February 16 at 7:10 PM
News IconTechnical Toolbox: Investor Focus on Recro Pharma Inc. (REPH) - Sherwood Daily (NASDAQ:REPH)
sherwooddaily.com - February 4 at 7:35 PM
News IconInside Track: Trading Focus on Shares of Recro Pharma Inc. (REPH ... - Sherwood Daily (NASDAQ:REPH)
sherwooddaily.com - February 2 at 4:10 AM
News IconInside Track: Trading Focus on Shares of Recro Pharma Inc. (REPH) - Sherwood Daily (NASDAQ:REPH)
sherwooddaily.com - February 1 at 11:10 PM
News IconStock Checkup: Technical Watch on Recro Pharma Inc. (REPH) - Rives Journal (NASDAQ:REPH)
rivesjournal.com - January 29 at 12:42 AM
News IconRecro Pharma, Inc. (REPH) Under Analyst Spotlight - UK Market News (NASDAQ:REPH)
www.ukmarketnews.co.uk - January 28 at 6:07 AM
News IconEarnings Take Center Stage; Analysts Weighing in on Recro Pharma, Inc. (NASDAQ:REPH) - Aiken Advocate (NASDAQ:REPH)
aikenadvocate.com - January 28 at 6:07 AM
News IconADX, MA, and RSI in Focus for Recro Pharma Inc. (REPH) - Sherwood Daily (NASDAQ:REPH)
sherwooddaily.com - January 28 at 6:07 AM
News IconMy Watchlist for Friday, January 27 (NASDAQ:REPH)
ac-investor.blogspot.com - January 27 at 2:08 AM
News IconTrading Views: Checking the Numbers for Recro Pharma Inc. (REPH) - Sherwood Daily (NASDAQ:REPH)
sherwooddaily.com - January 26 at 3:17 AM
News IconChecking the Piotroski Score on Shares of Recro Pharma, Inc. (NASDAQ:REPH) - The Tribune (NASDAQ:REPH)
lakecitytribune.com - January 25 at 2:21 AM
News IconTop Stock With Upside & Growth Potential: Recro Pharma, Inc. (NASDAQ:REPH) - Prospect Journal (NASDAQ:REPH)
prospectjournal.com - January 23 at 7:49 PM
News IconA Quick Look At Recro Pharma (NASDAQ:REPH)
www.talkmarkets.com - January 23 at 12:17 AM
News IconSell-side Consensus Sees Recro Pharma, Inc. (NASDAQ:REPH) Going Where Near-Term? - Aiken Advocate (NASDAQ:REPH)
aikenadvocate.com - January 22 at 7:17 PM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: Recro Pharma, Inc. (NASDAQ:REPH) - Wall Street Beacon (NASDAQ:REPH)
wsbeacon.com - January 22 at 7:17 PM
News IconMoving Averages in Focus on Shares of Recro Pharma Inc. (REPH) - Sherwood Daily (NASDAQ:REPH)
sherwooddaily.com - January 20 at 6:28 AM
finance.yahoo.com logoExclusive: Recro Pharma CEO Talks Meloxicam, Alleviating Investor Concerns (NASDAQ:REPH)
finance.yahoo.com - January 18 at 8:08 PM
News IconTracking Corporate Insiders: What Are They Doing With Recro Pharma, Inc. (NASDAQ:REPH) - Wall Street Beacon (NASDAQ:REPH)
wsbeacon.com - January 18 at 12:55 AM
News IconWatching the Charts on Shares of Recro Pharma Inc. (REPH) - Sherwood Daily (NASDAQ:REPH)
sherwooddaily.com - January 18 at 12:55 AM
News IconStock Momentum Skidding to a Halt For Recro Pharma, Inc. (NASDAQ:REPH) - Wall Street Beacon (NASDAQ:REPH)
wsbeacon.com - January 18 at 12:55 AM
News IconRecro Pharma Inc REPH Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:REPH)
www.bioportfolio.com - January 11 at 8:13 PM
marketexclusive.com logoRecro Pharma, Inc. (NASDAQ:REPH) Files An 8-K Other Events - Market Exclusive (NASDAQ:REPH)
marketexclusive.com - January 9 at 7:36 AM
News IconHome Business Recro Pharma Inc. (NASDAQ: REPH) Stock Coverage Initiated at Janney Montgomery Scott - BNB Daily (blog) (NASDAQ:REPH)
www.baseball-news-blog.com - January 6 at 1:26 AM
seekingalpha.com logoRecro Pharma: Still More Upside Left - Seeking Alpha (NASDAQ:REPH)
seekingalpha.com - December 31 at 8:08 AM
4-traders.com logoRecro Pharma Inc :. (REPH) Given Average Rating of Buy by Analysts (NASDAQ:REPH)
www.4-traders.com - December 22 at 2:19 AM
News IconTechnical Toolbox: Investor Focus on Recro Pharma Inc. (REPH) - Yankee Analysts (NASDAQ:REPH)
yankeeanalysts.com - December 21 at 9:17 PM
News IconChecking in on Signals for Recro Pharma Inc. (REPH) - Yankee Analysts (NASDAQ:REPH)
yankeeanalysts.com - December 20 at 7:12 PM
finance.yahoo.com logoCoverage initiated on Recro Pharma by Piper Jaffray (NASDAQ:REPH)
finance.yahoo.com - December 20 at 2:10 PM
4-traders.com logoRECRO PHARMA, INC. : Other Events (form 8-K) (NASDAQ:REPH)
www.4-traders.com - December 19 at 12:54 AM
4-traders.com logoRecro Pharma : Announces Closing of $40 Million Public Offering of Common Stock (NASDAQ:REPH)
www.4-traders.com - December 17 at 2:20 AM
publicnow.com logoRecro Pharma Announces Closing of $40 Million Public Offering of Common Stock (NASDAQ:REPH)
www.publicnow.com - December 16 at 9:17 PM
biz.yahoo.com logoRECRO PHARMA, INC. Files SEC form 8-K, Other Events (NASDAQ:REPH)
biz.yahoo.com - December 16 at 9:17 PM
seekingalpha.com logoRecro Pharma Prices $39 Million New Offering - Seeking Alpha (NASDAQ:REPH)
seekingalpha.com - December 16 at 5:30 AM
News IconMarket Corner: Eye on Technicals for Recro Pharma Inc. (REPH) - Yankee Analysts (NASDAQ:REPH)
yankeeanalysts.com - December 16 at 5:30 AM
finance.yahoo.com logoRecro Pharma Announces Pricing of Public Offering of Common Stock (NASDAQ:REPH)
finance.yahoo.com - December 13 at 7:52 PM
finance.yahoo.com logo9:11 am Recro Pharma prices underwritten public offering of 6,500,000 shares of its common stock at $6.00/share (NASDAQ:REPH)
finance.yahoo.com - December 13 at 7:52 PM
bizjournals.com logoHere's how a Malvern pharma firm plans to spend its $36M in stock proceeds (NASDAQ:REPH)
www.bizjournals.com - December 13 at 7:52 PM
News IconRange Watch on Technical Indicators for Recro Pharma Inc. (REPH) - Yankee Analysts (NASDAQ:REPH)
yankeeanalysts.com - December 13 at 8:30 AM
capitalcube.com logoETFs with exposure to Recro Pharma, Inc. : December 12, 2016 (NASDAQ:REPH)
www.capitalcube.com - December 12 at 7:36 PM
247wallst.com logoRecro Pharma Secondary Offering (UPDATE) - 24/7 Wall St. (NASDAQ:REPH)
247wallst.com - December 9 at 8:00 AM
streetinsider.com logoRecro Pharma (REPH) Plans Offering of Common Stock - StreetInsider.com (NASDAQ:REPH)
www.streetinsider.com - December 9 at 12:59 AM
streetinsider.com logoRecro Pharma (REPH) Plans Offering of Common Stock (NASDAQ:REPH)
www.streetinsider.com - December 8 at 7:58 PM
finance.yahoo.com logoRecro Pharma Secondary Offering (UPDATE) (NASDAQ:REPH)
finance.yahoo.com - December 8 at 7:58 PM
biz.yahoo.com logoRECRO PHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits (NASDAQ:REPH)
biz.yahoo.com - December 8 at 8:53 AM
benzinga.com logoRecro Pharma CEO Discusses Strong Results In Non-Opioid Pain Treatment Study - Benzinga (NASDAQ:REPH)
www.benzinga.com - December 2 at 11:54 AM
News IconTechnical Watch on These Shares: Recro Pharma Inc. (REPH) - Yankee Analysts (NASDAQ:REPH)
yankeeanalysts.com - December 2 at 11:54 AM

Social

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

Where is Recro Pharma's stock going? Where will Recro Pharma's stock price be in 2017?

6 brokerages have issued twelve-month price targets for Recro Pharma's shares. Their forecasts range from $12.00 to $24.00. On average, they anticipate Recro Pharma's stock price to reach $19.67 in the next twelve months.

When will Recro Pharma announce their earnings?

Recro Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, March, 22nd 2017.

Who owns Recro Pharma stock?

Recro Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Broadfin Capital, LLC (16.43%), Broadfin Capital LLC (25.49%), Stonepine Capital Management, LLC (15.20%), Stonepine Capital Management LLC (23.63%), Deerfield Management Co. (17.06%) and Deerfield Mgmt, LP (10.90%). Company insiders that own Recro Pharma stock include Alfred Altomari, Charles Garner, Donna Nichols, Geraldine Henwood, Healthcare Master Fun Broadfin, Karen Flynn, Randall Mack, Scp Vitalife Partners (Israel), Scp Vitalife Partners Ii Lp, Stewart Mccallum and Winston J Churchill.

Who sold Recro Pharma stock? Who is selling Recro Pharma stock?

Recro Pharma's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have sold Recro Pharma stock in the last year include Scp Vitalife Partners (Israel), Scp Vitalife Partners Ii Lp and Winston J Churchill.

Who bought Recro Pharma stock? Who is buying Recro Pharma stock?

Recro Pharma's stock was acquired by a variety of institutional investors in the last quarter, including Deerfield Management Co., Stonepine Capital Management LLC, Alyeska Investment Group L.P., Broadfin Capital LLC, Acuta Capital Partners LLC, Kingdon Capital Management L.L.C., Cadence Capital Management LLC and Numeric Investors LLC. Company insiders that have bought Recro Pharma stock in the last two years include Alfred Altomari, Charles Garner, Donna Nichols, Geraldine Henwood, Healthcare Master Fun Broadfin, Karen Flynn, Randall Mack and Stewart Mccallum.

How do I buy Recro Pharma stock?

Shares of Recro Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Recro Pharma stock cost?

One share of Recro Pharma stock can currently be purchased for approximately $7.31.

Recro Pharma (NASDAQ:REPH) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Recro Pharma (NASDAQ:REPH)

Earnings History Chart

Earnings by Quarter for Recro Pharma (NASDAQ:REPH)

Dividend History Chart

Dividend Payments by Quarter for Recro Pharma (NASDAQ:REPH)

Last Updated on 2/27/2017 by MarketBeat.com Staff